MedTrace Logo

Multiple Ascending Dose Study of DW4421

NCT07691242 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2026-07-08

No results posted yet for this study

Summary

Multiple Ascending Dose of DW4421, phase I

Conditions

  • Healthy Adult Volunteers

Interventions

DRUG

DW4421S-T0

DW4421 5mg

DRUG

DW4421S-T2

DW4421 15mg

DRUG

DW4421S-T1

DW4421 20mg

DRUG

DW4421S-T3

DW4421 30mg

DRUG

DW4421S

DW4421 40mg

DRUG

DW4421-3

Zastaprazan 20mg

Sponsors & Collaborators

  • Daewon Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2026-12-31
Completion
2027-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07691242 on ClinicalTrials.gov